NS5B RNA dependent RNA polymerase inhibitors: The promising approach to treat hepatitis C virus infections

Current Medicinal Chemistry

Volumn 17, Issue 32, 2010, Pages 3806-3826

  Deore, R R ^a   Chern, J W ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Active site; Allosteric site; Hepatitis C virus; Non nucleoside inhibitors; NS5B polymerase; Nucleoside inhibitors; Replicon activity; Structure activity relationship

Indexed keywords

2 AMINO 8 (BETA DEXTRORIBOFURANOSYL) IMIDAZO [1,2 A] S TRIAZINE 4 ONE; 2' FLUORORIBONUCLEOSIDE; 3' DEOXYCYTIDINE; 4 N HYDROXYCYTIDINE; 4' AZIDOCYTIDINE; ACICLOVIR; ADENOSINE DERIVATIVE; ALLOSTERIC SITE INHIBITOR; BENZIMIDAZOLE DERIVATIVE; BENZOTHIADIAZINE DERIVATIVE; BETA DEXTRO 2' DEOXY 2' FLUORO 2' C METHYLCYTIDINE; DIHYDROPYRIDINE DERIVATIVE; INTERFERON; NON NUCLEOSIDE INHIBITOR; NONSTRUCTURAL PROTEIN 5B; NONSTRUCTURAL PROTEIN 5B POLYMERASE INHIBITOR; PEGINTERFERON; PEGINTERFERON ALPHA; PROLINE SULFONAMIDE DERIVATIVE; PURINE NUCLEOSIDE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRIMIDINE NUCLEOSIDE INHIBITOR; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE INHIBITOR; SANGIVAMYCIN; TARIBAVIRIN; TOYACAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; VALOPICITABINE; ZX 2401;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ENZYME ACTIVE SITE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; REPLICON; STRUCTURE ACTIVITY RELATION; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REPLICATION; X RAY CRYSTALLOGRAPHY;

AMIDES; ANTIVIRAL AGENTS; AZOLES; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; HEPATITIS C; HUMANS; NUCLEOSIDES; PYRIMIDINES; RNA REPLICASE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 78650632021     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710793205471     Document Type: Article

References (118)

1. Choo, Q.; Kuo, G.; Weiner, A.; Overby, L.; Bradley, D.; Houghton, M. Isolation of a DNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, 1989, 244, 359-362.
2. Kuo, G.; Choo, Q.; Alter, H.; Gitnick, G.; Redeker, A.; Purcell, R.; Miyamura, T.; Dienstag, J.; Alter, M.; Stevens, C. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science, 1989, 244, 362-364.
3. Weiss, U. Hepatitis C. Nature, 2005, 436, 929.
4. Hoofnagle, J. H.; Mullen, K. D.; Jones, D. B.; Rustgi, V.; Di Bisceglie, A.; Peters, M.; Waggoner, J. G.; Park, Y.; Jones, E. A. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N. Engl. J. Med., 1986, 315, 1575-1578.
5. Di Bisceglie, A. M.; Hoofnagle, J. H. Optimal therapy of hepatitis C. Hepatology, 2002, 36, S121-127.
6. McHutchison, J. G.; Poynard, T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin. Liver Dis., 1999, 19 (Suppl. 1), 57-65.
7. Manns, M. P.; McHutchison, J. G.; Gordon, S. C.; Rustgi, V. K.; Shiffman, M.; Reindollar, R.; Goodman, Z. D.; Koury, K.; Ling, M.; Albrecht, J. K. PEGinterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 2001, 358, 958-965. (Pubitemid 32913521)
8. Fried, M. W.; Shiffman, M. L.; Reddy, K. R.; Smith, C.; Marinos, G.; Goncales, F. L. Jr.; Haussinger, D.; Diago, M.; Carosi, G.; Dhumeaux, D.; Craxi, A.; Lin, A.; Hoffman, J.; Yu, J. PEGinterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med., 2002, 347, 975-982.
9. Feld, J. J.; Hoofnagle J. H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature, 2005, 436, 967-972.
10. Houghton, M.; Abrignani, S. Prospects for a vaccine against the hepatitis C virus. Nature, 2005, 436, 961-966.
11. Friebe, P.; Lohmann, V.; Krieger, N.; Bartenschlager, R. Sequences in the 5′ nontranslated region of hepatitis C virus required for RNA replication. J. Virol, 2001, 75, 12047-12057. (Pubitemid 33115877)
12. Friebe, P.; Bartenschlager, R. Genetic analysis of sequences in the 3' nontranslated region of hepatitis C virus that are important for RNA replication. J. Virol, 2002, 76, 5326-5338.
13. Spahn, CM.; Kieft, J. S.; Grassucci, R. A.; Penczek, PA.; Zhou, K.; Doudna, J. A.; Frank, J. Hepatitis C virus IRES RNA-induced changes in the conformation of the 40S ribosomal subunit. Science, 2001, 291, 1959-1962.
14. Ito, T.; Tahara, S. M.; Lai, M. M. The 3'-untranslated region of hepatitis C virus RNA enhances translation from an internal ribosomal entry site. J. Virol, 1998, 72, 8789-8796.
15. Manns, M. P.; Foster, G. R.; Rockstroh, J. K.; Zeuzem, S.; Zoulim, F.; Houghton, M. The way forward in HCV treatment-finding the right path. Nat. Rev. Drug Discov., 2007, 6, 991-1000.
16. Huang, Z.; Murray, M. G.; Secrist III, J. A. Recent development of therapeutics for chronic HCV infection. Antiviral. Res., 2006, 71, 351-362.
17. Gordon, C. P.; Keller PA. Control of hepatitis C: a medicinal chemistry perspective. J. Med. Chem., 2005, 48, 1-20.
18. Tan, S. L.; Pause, A.; Shi, Y.; Sonenberg, N. Hepatitis C therapeutics: current status and emerging strategies. Nat. Rev. Drug Discovery, 2002, 1, 867-881.
19. Walker, M. P.; Hong, Z. HCV RNA-dependent RNA polymerase as a target for antiviral development. Curr. Opin. Pharmacol, 2002, 2, 534-540.
20. Ilan, E.; Arazi, J.; Nussbaum, O.; Zauberman, A.; Eren, R.; Lubin, I.; Neville, L.; Ben-Moshe, O.; Kischitzky, A.; Litchi, A.; Margalit, I.; Gopher, J.; Mounir, S.; Cai, W.; Daudi, N.; Eid, A.; Jurim, O.; Czerniak, A.; Galun, E.; Dagan, S. The hepatitis C virus (HCV) - Trimera mouse: a model for evaluation of agents against HCV. J. Infect. Dis., 2002, 185, 153-161.
21. Mercer, D. F.; Schiller, D. E.; Elliott, J. F.; Douglas, D. N.; Hao, C.; Rinfret, A.; Addison, W. R.; Fischer, K. P.; Churchill, T. A.; Lakey, J. R. T.; Tyrrell, D. L. J.; Kneteman, N. M. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med., 2001, 7, 927-933.
22. Condon, S. M.; Laporte, M. G.; Herbertz, T. Allosteric inhibitors of hepatitis C NS5B RNA-dependent RNA polymerase. Curr. Med. Chem. Anti-Infect. Agents, 2005, 4, 99-110.
23. Wu, J. Z.; Yao, N.; Walker, M.; Hong, Z. Recent advances in discovery and development of promising therapeutics against hepatitis C virus NS5B RNA-dependent RNA polymerase. Mini-Rev. Med. Chem., 2005, 5, 1103-1112.
24. De Francesco, R.; Tomei, L.; Altamura, S.; Summa, V.; Migliaccio, G. Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral. Res., 2003, 58, 1-16.
25. Walker, M. P.; Appleby, T. C.; Zhong, W.; Lau, J. Y. N.; Hong, Z. Hepatitis C virus therapies: current treatments, targets and future perspectives. Antiviral Chem. Chemother, 2003, 14, 1-21.
26. Wu, J. Z.; Hong, Z. Targeting NS5B RNA-Dependent RNA polymerase for anti-HCV chemotherapy. Curr. Drug Targets Infect. Disord., 2003, 3, 207-219.
27. Lesburg, C. A.; Cable, M. B.; Ferrari, E.; Hong, Z.; Mannarino, A. F.; Weber, P. C. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C Virus reveals a fully encircled active site. Nat. Struct. Biol, 1999, 6, 937-943.
28. Bressanelli, S.; Tomei, L.; Roussel, A.; Incitti, I.; Vitale, R. L.; Mathieu, M.; De Francesco, R.; Rey, F. A. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl. Acad. Sci. USA, 1999, 96, 13034-13039.
29. Ago, H.; Adachi, T.; Yoshida, A.; Yamamoto, M.; Habuka, N.; Yatsunami, K.; Miyano, M. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure (Cambridge, U. K.), 1999, 7, 1417-1426.
30. Migliaccio, G.; Tomassini, J. E.; Carroll, S. S.; Tomei, L.; Altamura, S.; Bhat, B.; Bartholomew, L.; Bosserman, M. R.; Ceccacci, A.; Colwell, L. F.; Cortese, R.; DeFrancesco, R.; Eldrup, A. B.; Getty, K. L.; Hou, X. S.; LaFemina, R. L.; Ludmerer, S. W.; MacCoss, M.; McMasters, D. R.; Stahlhut, M. W.; Olsen, D. B.; Hazuda, D. J.; Flores, O. A. Characterization of resistance to non-obligate chainterminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J. Biol. Chem., 2003, 278, 49164-49170.
31. Sidwell, R. W.; Huffmann, J. H.; Khare, G. P.; Allen, L. B.; Witkowski, J. T.; Robins, R. K. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamide. Science, 1972, 177, 705-706.
32. Witkowski, J. T.; Robins, R. K.; Sidwell, R. W.; Simon, L. N. Design, synthesis, and broad spectrum antiviral activity of 1-beta-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamide and related nucleosides. J. Med. Chem., 1972, 15, 1150-1154.
33. Carroll, S. S.; Tomassini, J. E.; Bosserman, M.; Getty, K.; Stahlhut, M. W.; Eldrup, A. B.; Bhat, B.; Hall, D.; Simcoe, A. L.; LaFemina, R.; Rutkowski, C. A.; Wolanski, B.; Yang, Z.; Migliaccio, G.; De Francesco, R.; Kuo, L. C.; MacCoss, M.; Olsen, D. B. Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs. J. Biol. Chem., 2003, 278, 11979-11984.
34. Eldrup, A. B.; Prhavc, M.; Brooks, J.; Bhat, B.; Prakash, T. P.; Song, Q.; Bera, S.; Bhat, N.; Dande, P.; Cook, P. D.; Bennett, C. F.; Carroll, S. S.; Ball, R. G.; Bosserman, M.; Burlein, C.; Colwell, L. F.; Fay, J. F.; Flores, O. A.; Getty, K.; LaFemina, R. L.; Leone, J.; MacCoss, M.; McMasters, D. R.; Tomassini, J. E.; VonLangen, D.; Wolanski, B.; Olsen, D. B. Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication. J. Med. Chem., 2004, 47, 5284-5297. (Pubitemid 39314927)
35. Hecker, S. J.; Reddy, K. R.; van Poelje, P. D.; Sun, Z.; Huang, W.; Varkhedkar, V.; Reddy, M. V.; Fujitaki, J. M.; Olsen, B.; Koeplinger, K. A.; Boyer, S. H.; Linemeyer, D. L.; MacCoss, M.; Erion, M. D. Liver-targeted prodrugs of 2'-C-methyladenosine for therapy of hepatitis C virus infection. J. Med. Chem., 2007, 50, 3891-3896.
36. Gunic, E.; Rong F. 6-Hydrazinopurine 2'-methyl ribonucleosides and nucleotides for treatment of HCV. 2006, WO 2006/122207.
37. Gunic, E.; Girardet, J. L.; Ramasamy, K.; Stoisavljevic-Petkov, V.; Chow, S.; Yeh, L. T.; Hamatake, R. K.; Raney, A.; Hong, Z. Cyclic monophosphate prodrugs of base modified 2'-C-methyl ribonucleosides as potent inhibitors of hepatitis C virus RNA replication. Bioorg. Med. Chem. Lett., 2007, 17, 2452-2455.
38. Ding, Y.; Girardet, J. L.; Hong, Z.; Lai, V. C. H.; An, H.; Koh, Y. H.; Shaw, S. Z.; Zhong, W. Synthesis of 9-(2-beta-C-methyl-beta-dribofuranosyl)-6- substituted purine derivatives as inhibitors of HCV RNA replication. Bioorg. Med. Chem. Lett., 2005, 15, 709-713. (Pubitemid 40143152)
39. Gunic, E.; Chow, S.; Rong, F.; Ramasamy, K.; Raney, A.; Li, D. Y.; Huang, J.; Hamatake, R. K.; Hong, Z.; Girardet, J. L. 6-Hydrazinopurine 2'-methyl ribonucleosides and their 5'-monophosphate prodrugs as potent hepatitis C virus inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 2456-2458. (Pubitemid 46507790)
40. Eldrup, A. B.; Allerson, C. R.; Bennett, C. F.; Bera, S.; Bhat, B.; Bhat, N.; Bosserman, M. R.; Brooks, J.; Burlein, C.; Carroll, S. S.; Cook, P. D.; Getty, K. L.; MacCoss, M.; McMasters, D. R.; Olsen, D. B.; Prakash, T. P.; Prhavc, M.; Song, Q.; Tomassini, J. E.; Xia, J. Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase. J. Med. Chem., 2004, 47, 2283-2295.
41. Carroll, S. S.; Davies, M.; Handt, L.; Koeplinger, L. K.; Zhang, R.; Ludmerer, S.; MacCoss, M.; Hazuda, D.; Olsen, D. Robust suppression of viral replication by a nucleoside polymerase inhibitor in chimpanzees infected with hepatitis C virus. Hepatology, 2006, 44 (Suppl. 1), Abs. 935.
42. Ismaili, H. M. A.; Cheng, Y. X.; Lavallee, J. F.; Siddiqui, A.; Storer, R. Method for the treatment or prevention of flavivirus infections using nucleoside analogues. 2001, WO 2001060315.
43. Hocek, M.; Naus, P.; Pohl, R.; Votruba, I.; Furman, P. A.; Tharnish, P. M.; Otto, M. J. Cytostatic 6-arylpurine nucleosides. 6. SAR in anti-HCV and cytostatic activity of extended series of 6-hetarylpurine ribonucleosides. J. Med. Chem., 2005, 48, 5869-5873.
44. Clark, J. L.; Mason, J. C.; Hollecker, L.; Stuyver, L. J.; Tharnish, P. M.; McBrayer, T. R.; Otto, M. J.; Furman, P. A.; Schinazi, R. F.; Watanabe, K. A. Synthesis and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication. Bioorg. Med. Chem. Lett., 2006, 16, 1712-1715.
45. Yoo, B. N.; Kim, H. O.; Moon, H. R.; Seol, S. K.; Jang, S. K.; Lee, K. M.; Jeong, L. S. Synthesis of 2'-C-hydroxymethylribofuranosylpurines as potent anti-hepatitis C virus (HCV) agents. Bioorg. Med. Chem. Lett., 2006, 16, 4190-4194.
46. Ding, Y.; An, H.; Hong, Z.; Girardet, J. L. Synthesis of 2'-C-methyl toyocamycin and sangivamycin analogues as potential HCV inhibitors. Bioorg. Med. Chem. Lett., 2005, 15, 725-727.
47. Sommadossi, J. P.; La Colla, P. Methods and compositions using modified nucleosides for treating flaviviruses and pestiviruses. 2001, WO 2001092282.
48. Weller, S.; Blum, M. R.; Doucette, M.; Burnette, T.; Cederberg, D. M.; De Miranda, P.; Smiley, M. L. Pharmacokinetics of the acyclovir prodrug valaciclovir after escalating single and multiple dose administration to normal volunteers. Clin. Pharmacol. Ther., 1993, 54, 595-605.
49. Pierra, C.; Amador, A.; Benzaria, S.; Cretton-Scott, E.; D'Amours, M.; Mao, J.; Mathieu, S.; Moussa, A.; Bridges, E. G.; Standring, D. N.; Sommadossi, J. P.; Storer, R.; Gosselin, G. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine. J. Med. Chem., 2006, 49, 6614-6620.
50. Afdhal, N.; Rodriguez-Torres, M.; Lawitz, E.; Godofsky, E.; Chao, G.; Fielman, B.; Knox, S.; Brown, N. Enhanced antiviral efficacy for valopicitabine (NM283) plus PEG-Interferon in hepatitis C patients with HCV genotype-1 infection: results of a phase IIa multicenter trial. J. Hepatol., 2005, 42 (Suppl. 2), 39-40.
51. Lawitz, E.; Nguyen, T.; Younes, Z.; Santoro, J.; Gitlin, N.; McEniry, D.; Chasen, R.; Goff, J.; Knox, S.; Kleber, K.; Belanger, B.; Brown, N. A.; Dieterich, D. Valopicitabine (NM283) plus peginterferon in treatment naïve hepatitis C patients with HCV genotype-1 infection: HCV RNA clearance during 24 weeks of treatment. Hepatology, 2006, 44 (Suppl. 1), Abs. 93.
52. Smith, D. B.; Martin, J. A.; Smith, M.; Hobbs, C. J.; Merrett, J. H.; Sarma, K.; Klumpp, K.; Leveque, V.; Najera, I.; Jiang, W. R.; Devos, R.; Cammack, N. Synthesis and anti-hepatitis C virus activity of 4'-substituted ribonucleosides discovery of R1479. Presented at 19th International Conference on Antiviral Research (ICAR) 2006, San Juan, Puerto Rico, May 7-11, 2006.
53. McGuigan, C.; Cahard, D.; Sheeka, H. M.; De Clercq, E.; Balzarini, J. Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite. J. Med. Chem., 1996, 39, 1748-1753.
54. Perrone, P.; Luoni, G. M.; Kelleher, M. R.; Daverio, F.; Angell, A.; Mulready, S.; Congiatu, C.; Rajyaguru, S.; Martin, J. A.; Leveque, V.; Le Pogam, S.; Najera, I.; Klumpp, K.; Smith, D. B.; McGuigan, C. Application of the phosphoramidate ProTide approach to 4'-Azidouridine confers sub-micromolar potency versus hepatitis C virus on an inactive nucleoside. J. Med. Chem., 2007, 50, 1840-1849.
55. Ismaili, H. M. A.; Cheng, Y. X.; Lavallee, J. F.; Siddiqui, A.; Storer, R. Method for the treatment or prevention of flavivirus infections using nucleoside analogues. 2002, US 2002/0019363 A1.
56. Klumpp, K.; Leveque, V.; Le Pogam, S.; Ma, H.; Jiang, W. R.; Kang, H.; Granycome, C.; Singer, M.; Laxton, C.; Hang, J. Q.; Sarma, S.; Smith, D. B.; Heindl, D.; Hobbs, C. J.; Merrett, J. H.; Symons, J.; Cammack, N.; Martin, J. A.; Devos, R.; Najera, I. The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B dependent RNA synthesis and hepatitis C virus replication in cell culture. J. Biol. Chem., 2006, 281, 3793-3799.
57. Clark, J. L.; Hollecker, L.; Mason, J. C.; Stuyver, L. J.; Tharnish, P. M.; Lostia, S.; McBrayer, T. R.; Schinazi, R. F.; Watanabe, K. A.; Otto, M. J.; Furman, P. A.; Stec, W. J.; Patterson, S. E.; Pankiewicz, K. W. Design, synthesis, and antiviral activity of 2'-deoxy 2'-fluoro-2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication. J. Med. Chem., 2005, 48, 5504-5508.
58. Stuyver, L. J.; Whitaker, T.; McBrayer, T. R.; Hernandez-Santiago, B. I.; Lostia, S. Tharnish, P. M.; Ramesh, M.; Chu, C. K.; Jordon, R.; Shi, J.; Rachakonda, S. Ribonucleoside analog that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob. Agents Chemother., 2003, 47, 244-254.
59. Stuyver, L. J.; McBrayer, T. R.; Whitaker, T.; Tharnish, P. M.; Ramesh, M.; Lostia, S.; Cartee, L.; Shi, J.; Hobbs, A.; Schinazi, R. F.; Watanabe, K. A.; Otto, M. J. Inhibition of the subgenomic hepatitis C virus replicon in Huh-7 cells by 2'-deoxy-2'-fluorocytidine. Antimicrob. Agents Chemother, 2004, 48, 651-654.
60. Storer, R. Nucleoside derivatives for treating viral diseases. 2001, WO 01/32153 A2.
61. Wu, J. Z.; Walker, H.; Lau, J. Y.; Hong, Z. Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions. Antimicrob. Agents Chemother, 2003, 47, 426-431.
62. Barnard, D. Viramidine (Ribapharm). Curr Opin. Investig. Drugs, 2002, 3, 1585-1589.
63. Lin, C. C.; Yeh, L. T.; Vitarella, D.; Hong, Z. Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals. Antiviral. Chem. Chemother, 2003, 14, 145-152.
64. Zhu, R.; Wang, M.; Xia, Y.; Qu, F.; Neyts, J.; Peng, L. Arylethynyltriazole acyclonucleosides inhibit hepatitis C virus replication. Bioorg. Med. Chem. Lett., 2008, 18, 3321-3327.
65. Koh, Y. H.; Shim, J. H.; Girardet, J. L.; Hong, Z. Design and evaluation of a potential mutagen for Hepatitis C virus. Bioorg. Med. Chem. Lett., 2007, 17, 5261-5264.
66. Ojwang, J. O.; Ali, S.; Smee, D. F.; Morrey, J. D.; Shimasaki, CD.; Sidwell, R. W. Broad-spectrum inhibitor of viruses in the Flaviviridae family. Antiviral Res., 2005, 68, 49-55.
67. Blight, K. J.; Kolykhalov, A. A.; Rice, CM. Efficient initiation of HCV RNA replication in cell culture. Science, 2000, 290, 1870-1871.
68. Stuyver, L. J.; McBrayer, T. R.; Tharnish, P. M.; Hassan, A. E.; Chu, C. K.; Pankiewicz, K. W.; Watanabe, K. A.; Schinazi, R. F.; Otto, M. J. Dynamics of subgenomic hepatitis C virus replicon RNA levels in Huh-7 cells after exposure to nucleoside antimetabolites. J. Virol, 2003, 77, 10689-10694.
69. Summa, V.; Petrocchi, A.; Pace, P.; Matassa, V. G.; De Francesco, R.; Altamura, S.; Tomei, L.; Koch, U.; Neuner, P. Discovery of ay,-gamma-diketo acids as potent selective and reversible inhibitors of hepatitis C virus NS5b RNA-dependent RNA polymerase. J. Med. Chem., 2004, 47, 14-17.
70. Pace, P.; Nizi, E.; Pacini, B.; Pesci, S.; Matassa, V.; De Francesco, R.; Altamura, S.; Summa, V. The monoethyl ester of meconic acid is an active site inhibitor of HCV NS5B RNA-dependent RNA polymerase. Bioorg. Med. Chem. Lett., 2004, 14, 3257-3261.
71. Summa, V.; Petrocchi, A.; Matassa, V. G.; Taliani, M.; Laufer, R.; De Francesco, R.; Altamura, S.; Pace, P. HCV NS5b RNA-dependent RNA polymerase inhibitors: from alpha, gammadiketoacids to 4, 5-dihydroxypyrimidine-or 3-methyl-5 hydroxypyrimidinone carboxylic acids. Design and synthesis. J. Med. Chem., 2004, 47, 5336-5339.
72. Stansfield, I.; Avolio, S.; Colarusso, S.; Gennari, N.; Narjes, F.; Pacini, B.; Ponzi, S.; Harper, S. Active site inhibitors of HCV NS5B polymerase. The development and pharmacophore of 2-thienyl-5, 6-dihydroxypyrimidine-4- carboxylic acid. Bioorg. Med. Chem. Lett., 2004, 14, 5085-5088. (Pubitemid 39233371)
73. Koch, U.; Attenni, B.; Malancona, S.; Colarusso, S.; Conte, I.; Di Filippo, M.; Harper, S.; Pacini, B.; Giomini, C.; Thomas, S.; Incitti, I.; Tomei, L.; De Francesco, R.; Altamura, S.; Matassa, V. G.; Narjes, F. 2-(2-Thienyl)-5, 6-dihydroxy-4-carboxypyrimidines as inhibitors of the hepatitis C virus NS5B polymerase: discovery, SAR, modeling, and mutagenesis. J. Med. Chem., 2006, 49, 1693-1705.
74. Yan, S.; Appleby, T.; Gunic, E.; Shim, J. H.; Tasu, T.; Kim, H.; Rong, F.; Chen, H.; Hamatake, R.; Wu, J. Z.; Hong, Z.; Yao, Y. Isothiazoles as active-site inhibitors of HCV NS5B polymerase. Bioorg. Med. Chem. Lett., 2007, 17, 28-33.
75. Rockway, T. W.; Zhang, R.; Liu, D.; Betebenner, D. A.; McDaniel, K. F.; Beno, D.; Montgomery, D.; Jiang, W. W.; Masse, S.; Kati, W. M.; Middleton, T.; Molla, A.; Maring, C. J.; Kempf, D. J. Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of N-1-benzyl and N-1-[3-methylbutyl]-4-hydroxy-1, 8-naphthyridon-3-yl benzothiadiazine analogs containing substituents on the aromatic ring. Bioorg. Med. Chem. Lett., 2006, 16, 3833-3838.
76. Donner, PL.; Xie, Q.; Pratt, J. K.; Maring, C. J.; Kati, W.; Jiang, W.; Liu, Y.; Koev, G.; Masse, S.; Montgomery, D.; Molla, A.; Kempf, D. J. Des-A-ring benzothiadiazines: inhibitors of HCV genotype 1 NS5B RNA-dependent RNA polymerase. Bioorg. Med. Chem. Lett., 2008, 18, 2735-2738.
77. Zhou, Y.; Webber, S. E.; Murphy, D. E.; Li, L. S.; Dragovich, PS.; Tran, C. V.; Sun, Z.; Ruebsam, F.; Shah, A. M.; Tsan, M.; Showalter, R. E.; Patel, R.; Li, B.; Zhao, Q.; Han, Q.; Hermann, T.; Kissinger, C. R.; LeBrun, L.; Sergeeva, M. V.; Kirkovsky, L. Novel HCV NS5B polymerase inhibitors derived from 4-(1', 1'-dioxo-1', 4'-dihydro-1'γi6-benzo[1', 2', 4']thiadiazin-3'-yl)-5- hydroxy-2H-pyridazin-3-ones. Part 1: exploration of 7-substitution of benzothiadiazine. Bioorg. Med. Chem. Lett., 2008, 18, 1413-1419.
78. Zhou, Y.; Li, L. S.; Dragovich, PS.; Murphy, D. E.; Tran, C. V.; Ruebsam, F.; Webber, S. E.; Shah, A. M.; Tsan, M.; Averill, A.; Showalter, R. E.; Patel, R.; Han, Q.; Zhao, Q.; Hermann, T.; Kissinger, C. R.; LeBrun, L.; Sergeeva, M. V. Novel HCV NS5B polymerase inhibitors derived from 4-(1', 1'-dioxo-1', 4'-dihydro-1'}6-benzo[1', 2', 4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3- ones. Part 2: variation of the 2-and 6-pyridazinone substituents. Bioorg. Med. Chem. Lett., 2008, 18, 1419-1424.
79. Evans, K. A.; Chai, D.; Graybill, T. L.; Burton, G.; Sarisky, R. T.; Lin-Goerke, J.; Johnston, V. K.; Rivero, R. A. An efficient, asymmetric solid-phase synthesis of benzothiadiazine-substituted tetramic acids: potent inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. Bioorg. Med. Chem. Lett., 2006, 16, 2205-2208.
80. Tedesco, R.; Shaw, A. N.; Bambal, R.; Chai, D.; Concha, N. O.; Darcy, M. G.; Dhanak, D.; Fitch, D. M.; Gates, A.; Gerhardt, W. G.; Halegoua, D. L.; Han, C.; Hofmann, G. A.; Johnston, V. K.; Kaura, A. C.; Liu, N.; Keenan, R. M.; Goerke, J. L.; Sarisky, R. T.; Wiggall, K. J.; Zimmerman, M. N.; Duffy, K. J. 3-(1, 1-Dioxo-2H-(1, 2, 4) - benzothiadiazin-3-yl)-4-hydroxy-2 (1 H)-quinolinones, potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase. J. Med. Chem., 2006, 49, 971-983. (Pubitemid 43221645)
81. Beaulieu, PL.; Fazal, G.; Gillard, J.; Kukolj, G.; Austel, V. Viral polymerase inhibitors. 2002, US6479508B1.
82. LaPlante, S. R.; Cameron, D. R.; Aubry, N.; LeFebvre, S.; Kukolj, G.; Maurice, R.; Thibeault, D.; Lamarre, D.; Llinas-Brunet, M. Solution structure of substrate-based ligands when bound to hepatitis C virus NS3 protease domain. J. Biol. Chem., 1999, 274, 18618-18624.
83. Beaulieu, PL.; Bos, M.; Bousquet, Y.; DeRoy, P.; Fazal, G.; Gauthier, J.; Gillard, J.; Goulet, S.; McKercher, G.; Poupart, M. A.; Valois, S.; Kukolj, G. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency. Bioorg. Med. Chem. Lett., 2004, 14, 967-971. (Pubitemid 38167623)
84. Beaulieu, PL.; Bousquet, Y.; Gauthier, J.; Gillard, J.; Marquis, M.; McKercher, G.; Pellerin, C.; Valois, S.; Kukolj, G. Non-Nucleoside benzimidazole based allosteric inhibitors of the hepatitis C virus NS5B polymerase: inhibition of subgenomic hepatitis C virus RNA replicons in Huh-7 cells. J. Med. Chem., 2004, 47, 6884-6892.
85. Ishida, T.; Suzuki, T.; Hirashima, S.; Mizutani, K.; Yoshida, A.; Ando, I.; Ikeda, S.; Adachi, T.; Hashimoto, H. Benzimidazole inhibitors of hepatitis C virus NS5B polymerase: identification of 2-[(4-diarylmethoxy) phenyl]-benzimidazole. Bioorg. Med. Chem. Lett., 2006, 16, 1859-1863. (Pubitemid 43267365)
86. Hirashima, S.; Suzuki, T.; Ishida, T.; Noji, S.; Yata, S.; Ando, I.; Komatsu, M.; Ikeda, S.; Hashimoto, H. Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109. J. Med. Chem., 2006, 49, 4721-4736.
87. Li, H.; Tatlock, J.; Linton, A.; Gonzalez, J.; Borchardt, A.; Dragovich, P.; Jewell, T.; Prins, T.; Zhou, R.; Blazel, J.; Parge, H.; Love, R.; Hickey, M.; Doan, C.; Shi, S.; Duggal, R.; Lewis, C.; Fuhrman, S. Identification and structure-based optimization of novel dihydropyrones as potent HCV RNA polymerase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 4834-4838.
88. Li, H.; Linton, A.; Tatlock, J.; Gonzalez, J.; Borchardt, A.; Abreo, M.; Jewell, T.; Patel, L.; Drowns, M.; Ludlum, S.; Goble, M.; Yang, M.; Blazel, J.; Rahavendran, R.; Skor, H.; Shi, S.; Lewis, C.; Fuhrman, S. A. Allosteric inhibitors of hepatitis C polymerase: discovery of potent and orally bioavailable carbon-linked dihydropyrones. J. Med. Chem., 2007, 50, 3969-3972.
89. Gopalsamy, A.; Chopra, R.; Lim, K.; Ciszewski, G.; Shi, M.; Curran, K. J.; Sukits, S. F.; Svenson, K.; Bard, J.; Ellingboe, J. W.; Agarwal, A.; Krishnamurthy, G.; Howe, A. Y. M.; Orlowski, M.; Feld, B.; O'Connell, J.; Mansour, T. S. Discovery of proline sulfonamides as potent and selective hepatitis C virus NS5b polymerase inhibitors. Evidence for a new NS5b polymerase binding site. J. Med. Chem., 2006, 49, 3052-3055.
90. Nittoli, T.; Curran, K.; Insaf, S.; DiGrandi, M.; Orlowski, M.; Chopra, R.; Agarwal, A.; Howe, A. Y. M.; Prashad, A.; Floyd, M. B.; Johnson, B.; Sutherland, A.; Wheless, K.; Feld, B.; O'Connell, J.; Mansour, T. S.; Bloom, J. Identification of anthranilic acid derivatives as a novel class of allosteric inhibitors of hepatitis C NS5B polymerase. J. Med. Chem., 2007, 50, 2108-2116.
91. Harper, S.; Pacini, B.; Avolio, S.; Di Filippo, M.; Migliaccio, G.; Laufer, R.; De Francesco, R.; Rowley, M.; Narjes, F. Development and preliminary optimization of indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase. J. Med. Chem., 2005, 48, 1314-1317.
92. Harper, S.; Avolio, S.; Pacini, B.; Di Filippo, M.; Altamura, S.; Tomei, L.; Paonessa, G.; Di Marco, S.; Carfi, A.; Giuliano, C.; Padron, J.; Bonelli, F.; Migliaccio, G.; De Francesco, R.; Laufer, R.; Rowley, M.; Narjes, F. Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase. J. Med. Chem., 2005, 48, 4547-4557.
93. Stansfield, I.; Pompei, M.; Conte, I.; Ercolani, C.; Migliaccio, G.; Jairaj, M.; Giuliano, C.; Rowley, M.; Narjes, F. Development of carboxylic acid replacements in indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase. Bioorg. Med. Chem. Lett., 2007, 17, 5143-5149.
94. Burton, G.; Ku, T. W.; Carr, T. J.; Kiesow, T.; Sarisky, R. T.; Lin-Goerke, J.; Baker, A.; Earnshaw, D. L.; Hofmann, G. A.; Keenan, R. M.; Dhanak, D. Identification of small molecule inhibitors of the hepatitis C RNA-dependent RNA polymerase from a pyrrolidine combinatorial mixture. Bioorg. Med. Chem. Lett., 2005, 15, 1553-1556.
95. Burton, G.; Ku, T. W.; Carr, T. J.; Kiesow, T.; Sarisky, R. T.; Lin-Goerke, J.; Hofmann, G. A.; Slater, M. J.; Haigh, D.; Dhanak, D.; Johnson, V. K.; Parry, N. R.; Thommes, P. Studies on acyl pyrrolidine inhibitors of HCV RNA-dependent RNA polymerase to identify a molecule with replicon antiviral activity. Bioorg. Med. Chem. Lett., 2007, 17, 1930-1933.
96. Slater, M. J.; Amphlett, E. M.; Andrews, D. M.; Bravi, G.; Cheasty, A. G.; Corfield, J. A.; Ellis, M. R.; Fenwick, R. H.; Fernandes, S.; Guidetti, R.; Haigh, D.; Hartley, D. C.; Howes, P. D.; Jackson, D. L.; Jarvest, R. L.; Lovegrove, V. L. H.; Medhurst, K. J.; Parry, N. R.; Price, H.; Shah, P.; Singh, O. M. P.; Stocker, R.; Thommes, P.; Wilkinson, C.; Wonacott, A. Optimization of novel acyl pyrrolidine inhibitors of hepatitis C virus RNA-dependent RNA polymerase leading to a development candidate. J. Med. Chem., 2007, 50, 897-900.
97. Pfefferkorn, J. A.; Greene, M. L.; Nugent, R. A.; Gross, R. J.; Mitchell, M. A.; Finzel, B. C.; Harris, M. S.; Wells, P. A.; Shelly, J. A.; Anstadt, R. A.; Kilkuskie, R. E.; Kopta, L. A.; Schwende, F. J. Inhibitors of HCV NS5b polymerase. Part 1: evaluation of the southern region of (2Z)-2-(benzoylamino)- 3-(5-phenyl-2-furyl) acrylic acid. Bioorg. Med. Chem. Lett., 2005, 15, 2481-2486.
98. Pfefferkorn, J. A.; Nugent, R.; Gross, R. J.; Greene, M.; Mitchell, M. A.; Reding, M. T.; Funk, L. A.; Anderson, R.; Wells, P. A.; Shelly, J. A.; Anstadt, R.; Finzel, B. C.; Harris, M. S.; Kilkuskie, R. E.; Kopta, L. A.; Schwende, F. J. Inhibitors of HCV NS5b polymerase. Part 2: evaluation of the northern region of (2Z)-2-benzoylamino-3-(4-phenoxy-phenyl) acrylic acid. Bioorg. Med. Chem. Lett., 2005, 15, 2812-2818. (Pubitemid 40732226)
99. Yan, S.; Larson, G.; Wu, J. Z.; Appleby, T.; Ding, Y.; Hamatake, R.; Hong, Z.; Yao, N. Novel thiazolones as HCV NS5B polymerase allosteric inhibitors: further designs, SAR, and X-ray complex structure. Bioorg. Med. Chem. Lett., 2007, 17, 63-67.
100. Shipps Jr., G. W.; Deng, Y.; Wang, T.; Popovici-Muller, J.; Curran, P. J.; Rosner, K. E.; Cooper, A. B.; Girijavallabhan, V.; Butkiewicz, N.; Cable, M. Aminothiazole inhibitors of HCV RNA polymerase. Bioorg. Med. Chem. Lett., 2005, 15, 115-119.
101. Gopalsamy, A.; Aplasca, A.; Ciszewski, G.; Park, K.; Ellingboe, J. W.; Orlowski, M.; Feld, B.; Howe, A. Y. M. Design and synthesis of 3, 4-dihydro-1H-[1] benzothieno[2, 3-c]pyran and 3, 4-dihydro-1H-pyrano[3, 4-b]benzofuran derivatives as non-nucleoside inhibitors of HCV NS5B RNA dependent RNA polymerase. Bioorg. Med. Chem. Lett., 2006, 16, 457-460.
102. Gopalsamy, A.; Shi, M.; Ciszewski, G.; Park, K.; Ellingboe, J. W.; Orlowski, M.; Feld, B.; Howe, A. Y. M. Design and synthesis of 2, 3, 4, 9-tetrahydro-1H-carbazole and 1, 2, 3, 4-tetrahydro-cyclopenta [b]indole derivatives as non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA polymerase. Bioorg. Med. Chem. Lett., 2006, 16, 2532-2534.
103. Ikegashira, K.; Oka, T.; Hirashima, S.; Noji, S.; Yamanaka, H.; Hara, Y.; Adachi, T.; Tsuruha, J.; Doi, S.; Hase, Y.; Noguchi, T.; Ando, I.; Ogura, N.; Ikeda, S.; Hashimoto, H. Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors. J. Med. Chem., 2006, 49, 6950-6953.
104. Hirashima, S.; Oka, T.; Ikegashira, K.; Noji, S.; Yamanaka, H.; Hara, Y.; Goto, H.; Mizojiri, R.; Niwa, Y.; Noguchi, T.; Ando, I.; Ikeda, S.; Hashimoto, H. Further studies on hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors toward improved replicon cell activities: benzimidazole and structurally related compounds bearing the 2-morpholinophenyl moiety. Bioorg. Med. Chem. Lett., 2007, 17, 3181-3186.
105. Liu, Y.; Donner, P. L.; Pratt, J. K.; Jiang, W. W.; Ng, T.; Gracias, V.; Baumeister, S.; Wiedeman, P. E.; Traphagen, L.; Warrior, U.; Maring, C.; Kati, W. M.; Djuric, S. W.; Molla, A. Identification of halosalicylamide derivatives as a novel class of allosteric inhibitors of HCV NS5B polymerase. Bioorg. Med. Chem. Lett., 2008, 18, 3173-3177.
106. Antonysamy, S. S.; Aubol, B.; Blaney, J.; Browner, M. F.; Giannetti, A. M.; Harris, S. F.; Hebert, N.; Hendle, J.; Hopkins, S.; Jefferson, E.; Kissinger, C.; Leveque, V.; Marciano, D.; McGee, E.; Najera, I.; Nolan, B.; Tomimoto, M.; Torresa, E.; Wright, T. Fragment based discovery of hepatitis C virus NS5b RNA polymerase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 2990-2995.
107. Louise-May, S.; Yang, W.; Nie, X.; Liu, D.; Deshpande, M. S.; Phadke, A. S.; Huang, M.; Agarwal, A. Discovery of novel dialkyl substituted thiophene inhibitors of HCV by in silico screening of the NS5B RdRp. Bioorg. Med. Chem. Lett., 2007, 17, 3905-3909.
108. Ontoria, J. M.; Hernando, J. I. M.; Malancona, S.; Attenni, B.; Stansfield, I.; Conte, I.; Ercolani, C.; Habermann, J.; Ponzi, S.; Di Filippo, M.; Koch, U.; Rowley, M.; Narjes, F. Identification of thieno[3, 2-b]pyrroles as allosteric inhibitors of hepatitis C virus NS5B polymerase. Bioorg. Med. Chem. Lett., 2006, 16, 4026-4030. (Pubitemid 43903215)
109. Rong, F.; Chow, S.; Yan, S.; Larson, G.; Hong, Z.; Wu, J. Structure-activity relationship (SAR) studies of quinoxalines as novel HCV NS5B RNA-dependent RNA polymerase inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 1663-1666.
110. Ding, Y.; Girardet, J. L.; Smith, K. L.; Larson, G.; Prigaro, B.; Lai, V. C. H.; Zhong, W.; Wu, J. Z. Parallel synthesis of pteridine derivatives as potent inhibitors for hepatitis C virus NS5B RNA-dependent RNA polymerase. Bioorg. Med. Chem. Lett., 2005, 15, 675-678.
111. Nyanguile, O.; Pauwels, F.; Van den Broeck, W.; Boutton, C. W.; Quirynen, L.; Ivens, T.; Van der Helm, L.; Vandercruyssen, G.; Mostmans, W.; Delouvroy, F.; Dehertogh, P.; Cummings, M. D.; Bonfanti, J. F.; Simmen, K. A.; Raboisson, P. 1, 5-Benzodiazepines, a novel class of hepatitis C virus polymerase nonnucleoside inhibitors. Antimicrob. Agents Chemother., 2008, 52, 4420-4431.
112. McGowan, D.; Nyanguile, O.; Cummings, M. D.; Vendeville, S.; Vandyck, K.; Van den Broeck, W.; Boutton, C. W.; De Bondt, H.; Quirynen, L.; Amssoms, K.; Bonfanti, J. F.; Last, S.; Rombauts, K.; Tahri, A.; Hu, L.; Delouvroy, F.; Vermeiren, K.; Vandercruyssen, G.; Va n der Helm, L.; Cleiren, E.; Mostmans, W.; Lory, P.; Pille, G.; Van Emelen, K.; Fanning, G.; Pauwels, F.; Lin, T. I.; Simmen, K.; Raboisson, P. 1, 5-Benzodiazepine inhibitors of HCV NS5B polymerase. Bioorg. Med. Chem. Lett., 2009, 19, 2492-2496.
113. Puerstinger, G.; Paeshuyse, J.; Herdewijn, P.; Rozenski, J.; De Clercq, E.; Neyts, J. Substituted 5-benzyl-2-phenyl-5H-imidazo[4, 5-c]pyridines: a new class of pestivirus inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 5345-5349.
114. Puerstinger, G.; Paeshuyse, J.; De Clercq, E.; Neyts, J. Antiviral 2, 5-disubstituted imidazo[4, 5-c]pyridines: from anti-pestivirus to anti-hepatitis C virus activity. Bioorg. Med. Chem. Lett., 2007, 17, 390-393. (Pubitemid 46073753)
115. Puerstinger, G.; Paeshuyse, J.; Heinrich, S.; Mohr, J.; Schraffl, N.; De Clercq, E.; Neyts, J. Antiviral 2, 5-disubstituted imidazo[4, 5-c]pyridines:
116. LaPorte, M. G.; Lessen, T. A.; Leister, L.; Cebzanov, D.; Amparo, E.; Faust, C.; Ortlip, D.; Bailey, T. R.; Nitz, T. J.; Chunduru, S. K.; Young, D. C.; Burns, C. J. Tetrahydrobenzothiophene inhibitors of hepatitis C virus NS5B polymerase. Bioorg. Med. Chem. Lett., 2006, 16, 100-103.
117. Ding, Y.; Smith, K. L.; Varaprasad, C. V. N. S.; Chang, E.; Alexander, J.; Yao, N. Synthesis of thiazolone-based sulfonamides as inhibitors of HCV NS5B polymerase. Bioorg. Med. Chem. Lett., 2007, 17, 841-845. (Pubitemid 46108542)
118. Franciscus, A. Hepatitis C treatments in current clinical development. http://www.hcvadvocate.org.